Skip to main content
Log in

Comparison of the effects of haloperidol, remoxipride and raclopride on “pre”- and postsynaptic dopamine receptors in the rat brain

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

The ability of the dopamine receptor antagonists haloperidol, raclopride and remoxipride to prevent the B-HT 920-induced decrease in striatal and limbic L-DOPA accumulation in gamma-butyrolactone (GBL)- and NSD 1015-treated rats (termed ‘GBL-reversal’) was used to define the effects of these compounds on “presynaptic” dopamine receptors. The doses of the dopamine antagonists producing antagonism of GBL-reversal were in each case roughly similar to the doses required to increase dopamine turnover in striatal and limbic areas. The potencies of haloperidol, raclopride and remoxipride in the GBL model were compared with their potencies in behavioural models for postsynaptic dopamine receptors. Haloperidol produced antagonism of GBL-reversal over a similar dose range to that required for antagonism of apomorphine-induced hyperactivity and stereotypy syndromes. Raclopride was effective in the order of potency: antagonism of apomorphine-induced hyperactivity > antagonism of GBL-reversal > antagonism of apomorphine-induced stereotypy. For remoxipride, the dose-response curve for antagonism of GBL-reversal was superimposable over that for antagonism of apomorphine-induced stereotypies, with an ED50 value about 12 times higher than that for antagonism of apomorphine-induced hyperactivity. Thus, the relative potencies of dopamine receptor antagonists at “pre-” and postsynaptic dopamine receptors vary considerably from compound to compound.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Andén N-E (1980) Regulation of monoamine synthesis and utilization by receptors. In: Szekeres L (ed) Handbook of experimental pharmacology, vol 54/I. Springer, Berlin Heidelberg New York, pp 429–462

    Google Scholar 

  • Andén N-E, Golembiowska-Nikitin K, Thornström U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn-Schmiedeberg's Arch Pharmacol 321:100–104

    Google Scholar 

  • Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurones: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560–571

    Google Scholar 

  • Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunney WE (eds) Pre- and postsynaptic receptors. Marcel Dekker, New York, pp 49–65

    Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140–144

    Google Scholar 

  • Chesselet M-F (1984) Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Neuroscience 12:347–375

    Google Scholar 

  • Costall B, Naylor RJ (1973) The roles of telencephalic dopaminergic systems in the mediation of apomorphine-induced stereotyped behaviour. Eur J Pharmacol 24:8–24

    Google Scholar 

  • DiChiara G, Porceddu ML, Spano PF, Gessa GL (1977) Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate cyclase by kainic acid. Brain Res 130:374–382

    Google Scholar 

  • Fowler CJ, Thorell G, Andersson M, Magnusson O (1985) Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function? Naunyn-Schmiedeberg's Arch Pharmacol 331:12–19

    Google Scholar 

  • Hinzen D, Hornykiewicz O, Kobinger W, Pichler L, Pifl C, Schingnitz G (1986) The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. Eur J Pharmacol 131:75–86

    Google Scholar 

  • Kirk RE (1968) Experimental design: Procedures for the behavioural sciences. Brooks/Cole, Belmont

    Google Scholar 

  • Laschinski G, Kittner B, Bräutigam M (1984) Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphine. Naunyn-Schmiedeberg's Arch Pharmacol 327:114–118

    Google Scholar 

  • Magnusson O, Fowler CJ, Köhler C, Ögren S-O (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25:187–197

    Google Scholar 

  • Magnusson O, Mohringe B, Fowler CJ (1987a) Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation. J Neural Transm 69:163–177

    Google Scholar 

  • Magnusson O, Mohringe B, Thorell G, Lake-Bakaar DM (1987b) Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. Pharmacol Toxicol 60:368–373

    Google Scholar 

  • Martin GE, Williams M, Haubrich DR (1982) A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine (3-PPP) with selected dopamine agonists. J Pharmacol Exp Ther 223:298–304

    Google Scholar 

  • Ögren S-O, Hall H, Köhler C (1978) Studies on the stereoselective dopamine receptor blockade in the rat brain by rigid spiroamines. Life Sci 23:1769–1774

    Google Scholar 

  • Ögren S-O, Hall H, Köhler C, Magnusson O, Lindbom L-O, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474

    Google Scholar 

  • Ögren SO, Hall H, Köhler C, Magnusson O, Sjöstrand S-E (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287–294

    Google Scholar 

  • Rollema H, Westerink BHC, Grol CJ (1976) Correlation between neuroleptic-induced suppression of stereotyped behaviour and HVA concentrations in rat brain. J Pharm Pharmacol 28: 321–323

    Google Scholar 

  • Starke K, Späth L, Lang JD, Adelung C (1983) Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus. Naunyn-Schmiedeberg's Arch Pharmacol 323:298–306

    Google Scholar 

  • Walters JR, Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 296:5–14

    Google Scholar 

  • Westerink BHC (1979) The effects of drugs on dopamine biosynthesis and metabolism in the brain. In: Horn AS, Korf J, Westerink BHC (eds) The neurobiology of dopamine. Academic Press, London, pp 255–291

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Send offprint requests to O. Magnusson

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magnusson, O., Fowler, C.J., Mohringe, B. et al. Comparison of the effects of haloperidol, remoxipride and raclopride on “pre”- and postsynaptic dopamine receptors in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 337, 379–384 (1988). https://doi.org/10.1007/BF00169527

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00169527

Key words

Navigation